MX2022009347A - Terapia de combinacion para el tratamiento del crecimiento celular anormal. - Google Patents
Terapia de combinacion para el tratamiento del crecimiento celular anormal.Info
- Publication number
- MX2022009347A MX2022009347A MX2022009347A MX2022009347A MX2022009347A MX 2022009347 A MX2022009347 A MX 2022009347A MX 2022009347 A MX2022009347 A MX 2022009347A MX 2022009347 A MX2022009347 A MX 2022009347A MX 2022009347 A MX2022009347 A MX 2022009347A
- Authority
- MX
- Mexico
- Prior art keywords
- cell growth
- abnormal cell
- treating abnormal
- combination therapy
- inhibitor
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title abstract 2
- 230000010261 cell growth Effects 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 229940124783 FAK inhibitor Drugs 0.000 abstract 1
- 229940124647 MEK inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940125399 kras g12c inhibitor Drugs 0.000 abstract 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968615P | 2020-01-31 | 2020-01-31 | |
| US202063115433P | 2020-11-18 | 2020-11-18 | |
| PCT/US2021/015401 WO2021154929A1 (en) | 2020-01-31 | 2021-01-28 | Combination therapy for treating abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009347A true MX2022009347A (es) | 2022-12-15 |
Family
ID=77079417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009347A MX2022009347A (es) | 2020-01-31 | 2021-01-28 | Terapia de combinacion para el tratamiento del crecimiento celular anormal. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230103007A1 (enExample) |
| EP (1) | EP4096671B1 (enExample) |
| JP (1) | JP2023513015A (enExample) |
| KR (1) | KR20230011908A (enExample) |
| CN (1) | CN115279376A (enExample) |
| AU (1) | AU2021213753A1 (enExample) |
| BR (1) | BR112022015161A2 (enExample) |
| CA (1) | CA3168648A1 (enExample) |
| IL (1) | IL295117A (enExample) |
| MX (1) | MX2022009347A (enExample) |
| WO (1) | WO2021154929A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| EP4062914A4 (en) | 2019-11-18 | 2024-01-17 | Inxmed (Nanjing) Co., Ltd. | USE OF AN FAK INHIBITOR IN THE PREPARATION OF A DRUG FOR THE TREATMENT OF TUMORS PRESENTING AN NRAS MUTATION |
| AU2021206684B2 (en) | 2020-01-10 | 2024-01-18 | Immuneering Corporation | MEK inhibitors and therapeutic uses thereof |
| EP4101453A4 (en) | 2020-02-05 | 2024-05-15 | Inxmed (Nanjing) Co., Ltd. | COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS |
| ES3049298T3 (en) * | 2020-08-03 | 2025-12-16 | Inxmed Nanjing Co Ltd | Solid form of compound |
| WO2022165142A1 (en) * | 2021-01-29 | 2022-08-04 | Mirati Therapeutics, Inc. | Combination therapies |
| US12280055B2 (en) * | 2021-05-27 | 2025-04-22 | Mirati Therapeutics, Inc. | Combination therapies |
| TW202313044A (zh) * | 2021-08-16 | 2023-04-01 | 大陸商應世生物科技（南京）有限公司 | Ｉｎ１００１８與ｐｌｄ的聯用 |
| CN114133355B (zh) * | 2021-11-29 | 2023-09-15 | 郑州大学第一附属医院 | 一种2-苯基-1h-苯并咪唑类衍生物及其应用 |
| JP2024545147A (ja) * | 2021-12-10 | 2024-12-05 | ▲應▼世生物科技（南京）有限公司 | 腫瘍治療の医薬組合せ及び使用 |
| WO2023108110A2 (en) * | 2021-12-10 | 2023-06-15 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| CA3252402A1 (en) * | 2022-02-28 | 2025-07-07 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | COMPOUND USED AS A FAK INHIBITOR AND ITS USE |
| JP7565132B2 (ja) * | 2022-04-20 | 2024-10-10 | 中外製薬株式会社 | がんの治療又は予防用医薬 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| WO2023246869A1 (zh) * | 2022-06-24 | 2023-12-28 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
| CN119451679A (zh) * | 2022-08-24 | 2025-02-14 | 应世生物科技(南京)有限公司 | Fak抑制剂及微管抑制剂的药物组合及用途 |
| CN119947725A (zh) * | 2022-09-30 | 2025-05-06 | 应世生物科技(南京)有限公司 | Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途 |
| JP2026503267A (ja) * | 2023-01-06 | 2026-01-28 | エラスカ，インク． | Ｒａｆ阻害剤およびｋｒａｓ ｇ１２ｃ阻害剤の併用療法 |
| CN115845065A (zh) * | 2023-01-09 | 2023-03-28 | 江苏省原子医学研究所 | Fn/fak通路抑制剂在制备提高甲状腺癌放射性碘治疗敏感性的药物中的用途 |
| US12254987B2 (en) * | 2023-03-23 | 2025-03-18 | Certis Oncology Solutions, Inc. | Artificial intelligence for identifying one or more predictive biomarkers |
| WO2024199466A1 (zh) * | 2023-03-31 | 2024-10-03 | 应世生物科技(南京)有限公司 | 提高大分子药物在肿瘤组织中的浓度的方法 |
| WO2025079712A1 (ja) * | 2023-10-12 | 2025-04-17 | 中外製薬株式会社 | ドライバー変異を有するがん患者における分子標的薬併用療法 |
| WO2025106901A1 (en) * | 2023-11-17 | 2025-05-22 | Quanta Therapeutics, Inc. | Combination cancer therapies with a kras modulator and an rtk-mapk pathway inhibitor |
| WO2025149017A1 (zh) * | 2024-01-11 | 2025-07-17 | 四川弘合生物科技有限公司 | 一种包含榄香烯和激酶抑制剂的药物 |
| WO2025157162A1 (zh) * | 2024-01-22 | 2025-07-31 | 应世生物科技(南京)有限公司 | Fak抑制剂与kras g12c抑制剂的联用 |
| WO2025261307A1 (zh) * | 2024-06-17 | 2025-12-26 | 首药控股(北京)股份有限公司 | 治疗肿瘤的药物组合及用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105163584B (zh) * | 2013-03-05 | 2019-06-04 | 田纳西大学研究基金会 | 用于治疗癌症的化合物 |
| WO2015120289A1 (en) * | 2014-02-07 | 2015-08-13 | Verastem, Inc. | Methods and compositions for treating abnormal cell growth |
| US10532056B2 (en) * | 2015-06-29 | 2020-01-14 | Verastem, Inc. | Therapeutic compositions, combinations, and methods of use |
| US11286469B2 (en) * | 2017-11-09 | 2022-03-29 | Wisconsin Alumni Research Foundation | Combination chemotherapy for the treatment of cancer |
| WO2020023851A1 (en) * | 2018-07-26 | 2020-01-30 | Yale University | Bifunctional substitued pyrimidines as modulators of fak proteolyse |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| BR112022010278A2 (pt) * | 2019-11-27 | 2022-10-04 | Turning Point Therapeutics Inc | Terapia combinada que envolve compostos macrocíclicos de diarila |
-
2021
- 2021-01-28 WO PCT/US2021/015401 patent/WO2021154929A1/en not_active Ceased
- 2021-01-28 CN CN202180012207.9A patent/CN115279376A/zh active Pending
- 2021-01-28 AU AU2021213753A patent/AU2021213753A1/en active Pending
- 2021-01-28 KR KR1020227030021A patent/KR20230011908A/ko active Pending
- 2021-01-28 US US17/795,402 patent/US20230103007A1/en active Pending
- 2021-01-28 MX MX2022009347A patent/MX2022009347A/es unknown
- 2021-01-28 JP JP2022546004A patent/JP2023513015A/ja active Pending
- 2021-01-28 CA CA3168648A patent/CA3168648A1/en active Pending
- 2021-01-28 EP EP21747362.8A patent/EP4096671B1/en active Active
- 2021-01-28 BR BR112022015161A patent/BR112022015161A2/pt unknown
- 2021-01-28 IL IL295117A patent/IL295117A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230103007A1 (en) | 2023-03-30 |
| BR112022015161A2 (pt) | 2022-10-11 |
| EP4096671A4 (en) | 2024-02-28 |
| IL295117A (en) | 2022-09-01 |
| JP2023513015A (ja) | 2023-03-30 |
| EP4096671A1 (en) | 2022-12-07 |
| WO2021154929A1 (en) | 2021-08-05 |
| CN115279376A (zh) | 2022-11-01 |
| KR20230011908A (ko) | 2023-01-25 |
| EP4096671B1 (en) | 2026-05-06 |
| CA3168648A1 (en) | 2021-08-05 |
| AU2021213753A1 (en) | 2022-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009347A (es) | Terapia de combinacion para el tratamiento del crecimiento celular anormal. | |
| MX2023000589A (es) | Terapia de combinacion para tratar el crecimiento celular anormal. | |
| MX2026002043A (es) | Combinacion de los compuestos ch5126766 y vs-6063 para usarse en el tratamiento de cancer | |
| NZ784224A (en) | Parp1 inhibitors | |
| MX2024004444A (es) | Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras). | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| MX2025003821A (es) | Compuestos con actividad contra tumores mutantes de kras | |
| MX2023009223A (es) | Terapia combinada para el tratamiento del crecimiento celular anormal. | |
| JOP20250258A1 (ar) | مثبطات 2-آزا باي سيكلو هبتان kras | |
| EA202190630A1 (ru) | Способы комбинированной терапии | |
| CR20210415A (es) | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidoria en cdk2 | |
| EP4552631A3 (en) | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer | |
| AU2018372763A1 (en) | Materials and methods for treatment of autosomal dominant Retinitis Pigmentosa | |
| MX2023011856A (es) | Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer. | |
| WO2019169065A3 (en) | Wee1 kinase inhibitors and methods of treating cancer using the same | |
| PH12020552135A1 (en) | Kdm1a inhibitors for the treatment of disease | |
| CR20230604A (es) | Inhibidores de mutación de her2 | |
| MX2024008115A (es) | Tratamiento conjunto para tratamiento contra el cancer. | |
| CR20220548A (es) | Compuestos de azalactama como inhibidores de hpk1 | |
| WO2022240971A3 (en) | Kras g12d inhibitors and uses thereof | |
| PH12022550124A1 (en) | Enzyme inhibitors | |
| MX2021002349A (es) | Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. | |
| MX2025001982A (es) | Inhibidores de kif18a y usos de estos | |
| WO2022020353A3 (en) | Methods and compositions for treatment and prevention of coronavirus infection |